Organometallic ruthenium(II) arene compounds with antiangiogenic activity.
about
Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity.Hydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligandsNew water-soluble polypyridine silver(I) derivatives of 1,3,5-triaza-7-phosphaadamantane (PTA) with significant antimicrobial and antiproliferative activities.Allosteric cross-talk in chromatin can mediate drug-drug synergy.Expression proteomics study to determine metallodrug targets and optimal drug combinations.Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy.A streamlined search technology for identification of synergistic drug combinations.Functional consequences of prolactin signalling in endothelial cells: a potential link with angiogenesis in pathophysiology?Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion.Fighting Cancer with Transition Metal Complexes: From Naked DNA to Protein and Chromatin Targeting Strategies.Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity.Neutron activation increases activity of ruthenium-based complexes and induces cell death in glioma cells independent of p53 tumor suppressor gene.Dicarba-closo-dodecarborane-containing half-sandwich complexes of ruthenium, osmium, rhodium and iridium: biological relevance and synthetic strategies.Phosphino-carboxamides: the inconspicuous gems.Metallomics insights into the programmed cell death induced by metal-based anticancer compounds.The chicken chorioallantoic membrane model in biology, medicine and bioengineeringMetal-based drugs that break the rules.Regulating the anticancer properties of organometallic dendrimers using pyridylferrocene entities: synthesis, cytotoxicity and DNA binding studies.In vitro and in vivo evaluation of organometallic gold(I) derivatives as anticancer agents.Anticancer Organometallic Osmium(II)-p-cymene Complexes.Synthesis and characterization of a new class of anti-angiogenic agents based on ruthenium clusters.Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment.Organometallic anticancer agents that interfere with cellular energy processes: a subtle approach to inducing cancer cell death.From catalysts to bioactive organometallics: do Grubbs catalysts trigger biological effects?Microwave-Assisted Synthesis of Arene Ru(II) Complexes Induce Tumor Cell Apoptosis Through Selectively Binding and Stabilizing bcl-2 G-Quadruplex DNA.Structures and anti-cancer properties of two binuclear copper complexes.Evaluation of arene ruthenium(II) N-heterocyclic carbene complexes as organometallics interacting with thiol and selenol containing biomolecules.Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1.Nucleosome acidic patch-targeting binuclear ruthenium compounds induce aberrant chromatin condensation.Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action† †Electronic supplementary information (ESI) available: Experimental, crystallographic, biological and mass spectrometric data, full list of prTarget profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action.Perspectives of ruthenium(ii) polyazaaromatic photo-oxidizing complexes photoreactive towards tryptophan-containing peptides and derivatives.Organoruthenium Complexes with C^N Ligands are Highly Potent Cytotoxic Agents that Act by a New Mechanism of Action.Half sandwich Ru(ii)-acylthiourea complexes: DNA/HSA-binding, anti-migration and cell death in a human breast tumor cell line.Anti-Inflammatory Oxicams as Multi-donor Ligand Systems: pH- and Solvent-Dependent Coordination Modes of Meloxicam and Piroxicam to Ru and Os.Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development.Pseudo electron-deficient organometallics: limited reactivity towards electron-donating ligands.Antiangiogenic ruthenium(ii) benzimidazole complexes, structure-based activation of distinct signaling pathways.NanoSIMS analysis of an isotopically labelled organometallic ruthenium(II) drug to probe its distribution and state in vitro.Clioquinol-ruthenium complex impairs tumour cell invasion by inhibiting cathepsin B activity.
P2860
Q27682260-3A837D15-EC4F-40C2-AB1F-4BFEE7C2B614Q28834484-4D35AF99-602F-4EA5-A258-87A669AA4AF9Q30597215-CE763CB1-29CB-4A5E-8C28-30DDD9C19268Q30843868-842965B1-EA3D-4C6A-8727-711C11B5ED41Q33685955-CA3ED831-F87F-4AFB-9F19-5CDAB9132FC9Q35165488-92E3256F-1DE9-4D57-84B1-E7E3B5A6066DQ36101810-0BE4C79A-D26B-4EF3-9452-F315E2F01B30Q37294904-FEC37689-5238-4506-9E0F-17DAF246C35DQ37295545-2170A9BC-5B2F-4A4C-8A6B-7161DAB43DB8Q37337277-E689947F-2D45-4B6A-BD1E-9847D8EDD230Q37657640-310C7A30-6FD4-4BCB-9651-E18F2396F0C7Q37703236-769BC59D-463F-4C0E-98CA-38070C5D7211Q37981543-89AD9512-6352-4E4D-9A5B-A31F6E021EDEQ37997959-B0832B72-8199-4564-A910-6C7613E60931Q38199383-9A5C1D31-87EE-4B98-B9CB-E2E80F28C417Q38241348-B07E55C1-AD8B-484B-9C71-F382F517F4D9Q38714812-63F1C102-13BC-487C-BC15-B5DA6FAA20C0Q38770155-5C85EDA9-9DAF-4160-A081-200762DE1A67Q38827745-7B772625-2AC7-4C26-9AC0-CCE955B2114FQ38851401-4E9BA519-96CB-409C-AC4B-3CCCC0C7018DQ39178846-B1552E4C-C15B-443F-885B-A134B2B1171DQ39220891-B54CF194-9BA3-4F5B-B6EA-695F569E5521Q39229950-40835B41-87E7-4BF8-9A29-5227AB78200CQ39477359-DE0824E4-D0FC-4B35-A1F0-2D4671D056EDQ40967875-B500A779-0CCB-41E5-979D-CD347ACEF781Q44452152-13B92066-F2DD-468B-BB73-5139D36E8CDEQ44548288-EA059474-05CC-4CC9-A942-3893FEC8A726Q45158260-86DAE65B-78F9-4516-B79F-51BC40AE6D5BQ47152126-D099FE11-C731-44E0-BFD5-13ACD9B196D9Q47159745-7CE334B8-6E44-4A00-9200-D9CDFC045FC5Q47196925-0981C144-6171-4789-888C-B98C2FC3E76FQ47303088-999F51EA-B32A-4954-B09A-56BD00102D3BQ47784937-B53802D3-A6CD-42EC-A93B-5E44D966AD80Q47787149-4CB4464B-00A6-4E9D-925C-194A7889CB60Q48235861-A5934790-2071-46FC-A823-B03F87A369AAQ49687144-47BA72D2-E7A7-4761-85CF-9BB8418040C5Q50022263-7FA5C993-FC8E-4B49-9620-77FD7A51D9ABQ51013825-80F33C18-5A5D-49D6-B022-81629455985AQ51700817-215046FC-042A-4213-8CF8-0067C6E558A6Q51752552-8904A6DB-5E45-4287-9ECF-F2819BF26824
P2860
Organometallic ruthenium(II) arene compounds with antiangiogenic activity.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Organometallic ruthenium
@nl
Organometallic ruthenium(II) arene compounds with antiangiogenic activity.
@en
type
label
Organometallic ruthenium
@nl
Organometallic ruthenium(II) arene compounds with antiangiogenic activity.
@en
prefLabel
Organometallic ruthenium
@nl
Organometallic ruthenium(II) arene compounds with antiangiogenic activity.
@en
P2093
P50
P356
P1476
Organometallic ruthenium(II) arene compounds with antiangiogenic activity.
@en
P2093
Arjan W Griffioen
Hubert van den Bergh
Judy R van Beijnum
Patrycja Nowak-Sliwinska
P304
P356
10.1021/JM2002074
P407
P577
2011-05-16T00:00:00Z